 | Up a level |
Gautschi, O.; Mach, N.; Rothschild, S.; Li, Qiyu; Stahel, R. A.; Zippelius, A.; Cathomas, R.; Früh, M.; Betticher, D. C.; Peters, S.; Rauch, D.; Feilchenfeldt, J.; Bubendorf, L.; Savic, S.; Jaggi, Rolf; Oppliger Leibundgut, Elisabeth; Largiadèr, Carlo Rodolfo; Brutsche, M.; Pilop, C.; Stalder, L.; ... (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical lung cancer, 16(5), pp. 358-365. Elsevier 10.1016/j.cllc.2015.02.007
Brömme, J. O.; Schmücking, M.; Arnold, A.; Giger, R.; Rauch, D.; Leiser, D.; Plasswilm, L.; Geretschläger, A.; Ghadjar, P.; Aebersold, D. M. (2013). Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer. Strahlentherapie und Onkologie, 189(8), pp. 618-624. Heidelberg: Springer Berlin Heidelberg 10.1007/s00066-013-0397-z
